[go: up one dir, main page]

DE602004030899D1 - Neues screening-verfahren - Google Patents

Neues screening-verfahren

Info

Publication number
DE602004030899D1
DE602004030899D1 DE602004030899T DE602004030899T DE602004030899D1 DE 602004030899 D1 DE602004030899 D1 DE 602004030899D1 DE 602004030899 T DE602004030899 T DE 602004030899T DE 602004030899 T DE602004030899 T DE 602004030899T DE 602004030899 D1 DE602004030899 D1 DE 602004030899D1
Authority
DE
Germany
Prior art keywords
screening procedure
salt
new screening
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004030899T
Other languages
English (en)
Inventor
Yasuaki Ito
Ryo Fujii
Makoto Kobayashi
Shuji Hinuma
Tadatoshi Hashimoto
Yasuhiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE602004030899D1 publication Critical patent/DE602004030899D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Threshing Machine Elements (AREA)
DE602004030899T 2003-04-25 2004-04-23 Neues screening-verfahren Expired - Lifetime DE602004030899D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003122464 2003-04-25
PCT/JP2004/005947 WO2004097411A1 (ja) 2003-04-25 2004-04-23 新規スクリーニング方法

Publications (1)

Publication Number Publication Date
DE602004030899D1 true DE602004030899D1 (de) 2011-02-17

Family

ID=33410077

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004030899T Expired - Lifetime DE602004030899D1 (de) 2003-04-25 2004-04-23 Neues screening-verfahren

Country Status (5)

Country Link
US (2) US20060216286A1 (de)
EP (1) EP1619499B1 (de)
AT (1) ATE494550T1 (de)
DE (1) DE602004030899D1 (de)
WO (1) WO2004097411A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743944A4 (de) 2004-04-23 2011-01-05 Takeda Pharmaceutical Neues screening-verfahren
JP5128273B2 (ja) * 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ
CA2625282A1 (en) * 2005-10-20 2007-04-26 Viamet Pharmaceuticals, Inc. Screening for modulators of metalation pathways for metalloproteins
WO2008030252A2 (en) * 2005-10-20 2008-03-13 Viamet Pharmaceuticals, Inc. Compositions and methods of screening apoproteins
JP2009539362A (ja) * 2006-06-08 2009-11-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｇタンパク質共役型受容体３９（ｇｐｒ３９）

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6720146B2 (en) * 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001257406A1 (en) 2000-04-26 2001-11-07 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
CA2438030A1 (en) 2001-02-14 2002-10-10 Protein Design Labs Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
JP2003024070A (ja) * 2001-06-05 2003-01-28 Pharma Design Inc 新規なｇタンパク質共役型受容体タンパク質及びその遺伝子
JP2003047472A (ja) * 2001-08-01 2003-02-18 Takeda Chem Ind Ltd 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ

Also Published As

Publication number Publication date
EP1619499A4 (de) 2008-03-05
ATE494550T1 (de) 2011-01-15
US20060216286A1 (en) 2006-09-28
EP1619499B1 (de) 2011-01-05
WO2004097411A1 (ja) 2004-11-11
US20090227037A1 (en) 2009-09-10
US7972800B2 (en) 2011-07-05
EP1619499A1 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
DE60332320D1 (de) Neues screening-verfahren
EP1589106A4 (de) Adiponektin-rezeptor und dafür kodierendes gen
WO2002084286A1 (fr) Procede de criblage
EP1432433A4 (de) Antagonisten
PL348529A1 (en) Receptor based antagonists and methods of making and using
DE60217147D1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
WO2004056763A3 (en) Novel glucagon antagonists
DE602004030899D1 (de) Neues screening-verfahren
TW200635919A (en) Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof
WO2000050563A3 (en) G protein-coupled receptor resembling galanin receptors
ATE511644T1 (de) Neues screening-verfahren
WO2003021262A1 (fr) Procede de criblage
WO2003082320A1 (fr) Nouveau procede de criblage
ATE486962T1 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
DE602004023493D1 (de) Neues screening-verfahren
WO2003052078A3 (en) Insect g protein-coupled receptor genes and uses thereof
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
DK1633859T3 (da) Cellelinje og anvendelser heraf
WO2005100386A3 (en) Canine cold-and menthol-sensitive receptor 1
DE60322269D1 (de) Neuartiger lysophosphatidsäure-rezeptor
WO2004083394A3 (en) Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
DE60134427D1 (de) Exzitatorische aminosäure-rezeptor-antagonisten
AU2003303351A8 (en) Chimeric protein for the screening of agonists and antagonists of cell signalling pathways that are dependent on g-protein-coupled receptors